Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.08-30

In August 2026, Guardant Health said it would appeal a US District Court of Delaware final judgment in a patent dispute with TwinStrand Biosciences and the University of Washington, with execution of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2663044590?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","is_english":true,"pubTime":"2026-08-30 19:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663044590","market":"us","top_or_hot":-1,"title":"Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?","media":"Simply Wall St.","content":"<div>\n<p>In August 2026, Guardant Health said it would appeal a US District Court of Delaware final judgment in a patent dispute with TwinStrand Biosciences and the University of Washington, with execution of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-30 19:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In August 2026, Guardant Health said it would appeal a US District Court of Delaware final judgment in a patent dispute with TwinStrand Biosciences and the University of Washington, with execution of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti","article_id":"2663044590","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2663044590","pubTimestamp":1788088793,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In August 2026, Guardant Health said it would appeal a US District Court of Delaware final judgment in a patent dispute with TwinStrand Biosciences and the University of Washington, with execution of the judgment and collection of potential royalties paused during the appeal.\nThe court’s royalty order applies mainly to older Guardant tests, while Guardant reports that upgraded versions of key products such as Shield and Reveal, along with validated design changes to Guardant360, fall outside...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","HELX":"Franklin Genomic Advancements ETF","FFOX":"FUNDX FUTURE FUND OPPORTUNITIES ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4196":"保健护理服务","BK4588":"碎股","EKG":"First Trust Nasdaq Lux Digital Health Solutions ETF","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","GH":"Guardant Health Inc.","GNMX":"Corgi Genomics & Precision Medicine ETF","BK4535":"淡马锡持仓","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","GDOC":"Goldman Sachs Future Health Care Equity ETF","LFSC":"F/m Emerald Life Sciences Innovation ETF","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","GNOM":"Global X Genomics & Biotechnology ETF"},"translate_title":"Guardant Health (GH) 的专利上诉是否比特许权使用费更能重塑其竞争护城河？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1.5,"EKG":0.6,"GNOM":0.6,"GDOC":0.6,"LFSC":0.6,"GNMX":0.6,"HELX":0.6,"PTH":0.6,"FFOX":0.6},"content_text":"In August 2026, Guardant Health said it would appeal a US District Court of Delaware final judgment in a patent dispute with TwinStrand Biosciences and the University of Washington, with execution of the judgment and collection of potential royalties paused during the appeal. The court’s royalty order applies mainly to older Guardant tests, while Guardant reports that upgraded versions of key products such as Shield and Reveal, along with validated design changes to Guardant360, fall outside the current royalty scope. We’ll now explore how this litigation outcome and Guardant’s claim that newer products avoid ongoing royalties may influence its investment narrative. AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementGuardant Health Investment Narrative RecapTo own Guardant Health, you need to believe its blood based cancer tests can grow into a large, durable business despite ongoing losses and heavy investment. Right now, the key near term catalyst is broader reimbursement and usage of tests like Shield and Guardant360, while the biggest risk is that rising costs and legal overhangs weigh on cash flow. The TwinStrand judgment adds legal and financial uncertainty, but Guardant’s claim that newer products sit outside the royalty scope may limit its practical impact near term. Among recent updates, the May 2026 FDA approval of Guardant360 Liquid CDx stands out here. It broadened the test’s clinical footprint and integrated genomic and epigenomic data into a single blood draw, with wide payer coverage. This kind of regulatory and commercial progress is central to the thesis that Guardant can expand oncology revenue and improve its mix, which matters even more now that legacy products are tied up in royalty and damages disputes. Yet while growth headlines grab attention, investors should also be aware of the unresolved patent and royalty risk that could still... Read the full narrative on Guardant Health (it's free!)Guardant Health's narrative projects $2.5 billion revenue and $3.9 million earnings by 2029.Uncover how Guardant Health's forecasts yield a $171.08 fair value, a 6% upside to its current price.Exploring Other PerspectivesGH 1-Year Stock Price Chart The most optimistic analysts were assuming revenue could reach about US$3.6 billion and earnings about US$485.0 million by 2029, yet this legal setback highlights how quickly expectations around Shield reimbursement and guideline driven growth could be tested and why your view might differ sharply from theirs.Explore 3 other fair value estimates on Guardant Health - why the stock might be worth just $171.08!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Guardant Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Guardant Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Guardant Health's overall financial health at a glance.Curious About Other Options?Opportunities like this don't last. These are today's most promising picks. Check them out now:The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2663044590","isCrawlerRequest":true}